恩替卡韦分散片治疗慢性乙型病毒性肝炎慢加急性肝衰竭的近期疗效

发布时间：2018-06-03 05:26

本文选题：恩替卡韦分散片 + 博路定　；参考：《广东医学》2016年08期

【摘要】：目的探讨恩替卡韦分散片治疗慢性乙型病毒性肝炎慢加急性肝衰竭的近期临床疗效。方法回顾性分析我院收治的98例慢性乙型病毒性肝炎慢加急性肝衰竭患者的临床资料,分成观察组和对照组,两组均给予常规内科综合治疗,56例应用恩替卡韦分散片抗病毒治疗者为观察组,42例应用恩替卡韦片抗病毒治疗者为对照组。比较两组患者治疗后12周乙肝病毒DNA、肝功能、凝血酶原时间和治疗12周后病死率的差异。结果两组患者乙肝病毒DNA水平快速下降,治疗第12周时,观察组中40例(71.43%)乙肝病毒DNA500 IU/m L,对照组中31例(73.81%)乙肝病毒DNA500 IU/m L,两组比较差异无统计学意义(醊2=0.068,P0.05)。12周时,两组患者的丙氨酸转氨酶、天门氨酸转氨酶、总胆红素较治疗前显著下降,血清白蛋白明显提高,PT明显缩短,组间比较差异均无统计学意义(P0.05)。至12周时,观察组病死率32.14%(18/56),对照组病死率30.95%(13/42),两组比较差异无统计学意义(P0.05)。两组均无不良反应发生。结论恩替卡韦分散片治疗慢性乙型病毒性肝炎慢加急性肝衰竭时能取得较好的临床疗效,是一种快速、强效、安全的抗乙型肝炎病毒药物。
[Abstract]:Objective to investigate the short-term clinical effect of entecavir dispersible tablets in the treatment of chronic viral hepatitis B with acute liver failure. Methods the clinical data of 98 patients with chronic viral hepatitis B and acute hepatic failure were analyzed retrospectively and divided into observation group and control group. Both groups were treated with routine medical comprehensive therapy. 56 cases were treated with entecavir dispersible tablets as the observation group, 42 cases were treated with entecavir tablets as the control group. The difference of hepatitis B virus DNA, liver function, prothrombin time and mortality after 12 weeks treatment were compared between the two groups. Results the level of hepatitis B virus DNA decreased rapidly in the two groups. At the 12th week of treatment, 40 patients in the observation group (71.43) and 31 patients in the control group (73.81) were treated with hepatitis B virus DNA500 IU/m L. There was no significant difference between the two groups at week 12 (20.068) (P 0.05). The levels of alanine aminotransferase, aspartate aminotransferase and total bilirubin in the two groups were significantly lower than those before treatment, and the serum albumin level was significantly increased and PT was shortened. There was no significant difference between the two groups (P 0.05). At 12 weeks, the mortality of the observation group was 32.14 / 56, and that of the control group was 30.95 / 42. There was no significant difference between the two groups (P 0.05). No adverse reactions occurred in both groups. Conclusion Entecavir dispersible tablet is a rapid, effective and safe antiviral drug in the treatment of chronic hepatitis B with acute liver failure.
【作者单位】：川北医学院附属医院感染科;
【分类号】：R512.62;R575.3

【相似文献】